Immunochemotherapy and cancer derived exosomes: interplay between Damage Associated Molecular Patterns (DAMPs) and NK cells

Anno
2018
Proponente Alessandra Zingoni - Professore Associato
Sottosettore ERC del proponente del progetto
Componenti gruppo di ricerca
Abstract

Natural killer (NK) cells are innate cytotoxic cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance. Multiple myeloma (MM) is a hematological disease characterized by the expansion of transformed plasma cells in the bone marrow and NK cells have a key role in the surveillance of this type of tumor. Increasing evidence denote that therapies designed to kill cancer cells and to simultaneously sustain host antitumor immunity are an appealing strategy to control tumor growth. NK cells can either sense damaged cells through the recognition of different activating ligands and at the same time they are able to detect Damage associated molecular patterns (DAMPs) released by abnormal cells through Toll-like receptors. In the cross-talk between NK and malignant cells, tumor cells release a wide range of soluble factors and extracellular vesicles, including exosomes, that could modulate NK cell-mediated functions. Recently, the importance of reciprocal exchange of exosomes from both stromal and MM cells has emerged as a pivotal mechanism facilitating tumor growth and progression suggesting a role of exosomes in the cross-talk between MM and stromal cells but little is known about effect of MM-cell derived exosomes on immune cells in the tumor microenvironment. The major objective of this proposal is to delineate how the multiple mieloma derived exosomes contribute to regulate the NK cell-mediated functions with particular attention given to the exosomal DAMPs (i.e: Hsp70 and HMGB1) able to interact with TLR2. We will study how chemotherapy can affect the exosome release and the amount of DAMPs associated to these nanovesicles and how this circumstance might affect their biological activity. These results point to improve either the efficacy of chemotherapy to boost the immune response and also to design new immunostimulatory nanoparticles to be used in combination with chemotherapy.

ERC
LS6_1, LS6_3, LS6_4
Keywords:
IMMUNITA¿ INNATA, CANCRO, CHEMIOTERAPIA

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma